Related Experiment Videos
Summary
Familial amyloidotic polyneuropathy (FAP), a rare but frequent amyloidosis, is endemic in Majorca. Advances in diagnosis, treatment, and genetic counseling offer hope for controlling and eradicating this degenerative disease.
Area of Science:
- Neurology
- Genetics
- Epidemiology
Context:
- Familial amyloidotic polyneuropathy (FAP), also known as Corino Andrade disease, represents a significant yet underrecognized form of amyloidosis.
- The Majorcan population has been identified as the fifth endemic focus worldwide for FAP, with diagnoses dating back to 1976.
Purpose:
- To summarize the epidemiologic and clinical characteristics of FAP patients in Majorca.
- To review scientific advancements crucial for managing and potentially eradicating FAP.
- To highlight the importance of increased awareness due to FAP's progressive incidence and varied presentation in Spain.
Summary:
- Epidemiologic and clinical data from Majorcan FAP patients diagnosed since 1976 are presented.
- Key scientific breakthroughs enabling early diagnosis of patients and asymptomatic carriers are discussed.
- Etiopathogenetic treatments and genetic counseling strategies aimed at disease eradication are highlighted.
Impact:
- Improved diagnostic methods facilitate early identification of individuals with FAP and carriers.
- Advancements in etiopathogenetic treatments offer new therapeutic avenues for FAP management.
- Genetic counseling empowers families to understand risks and make informed reproductive decisions, contributing to eradication efforts.